蕁麻疹治療の世界市場-2023年～2030年

市場概要

蕁麻疹治療の世界市場は、2022年に26億米ドルに達し、2023-2030年の予測期間中にCAGR 10.5％で成長し、2030年には57億米ドルに達すると予測されています。

世界の蕁麻疹治療市場は、主に有病率の増加により、近年著しい成長を遂げています。蕁麻疹の治療は慢性蕁麻疹と急性蕁麻疹のタイプに基づいて行われます。クリーブランド・クリニックによると、人口の約20％が少なくとも一度は蕁麻疹を発症します。人口の約1％から3％が慢性蕁麻疹です。

治療には抗ヒスタミン薬、抗炎症薬、かゆみ止め、局所麻酔薬、局所ステロイド薬、免疫抑制薬など多くの種類があります。最も一般的で効果的な治療薬は抗ヒスタミン薬です。全体として、世界市場は今後数年間で拡大すると予想されています。

蕁麻疹/蕁麻疹の有病率の増加、臨床試験や研究活動の増加、革新的な治療薬に対する需要の高まり、幅広い治療オプションの利用可能性、認知度の向上と早期発見、治療オプションの進歩などが、予測期間中に世界の蕁麻疹市場を牽引すると予想される主な要因です。

ダイナミクス

臨床試験の増加が蕁麻疹治療市場の成長を牽引

蕁麻疹治療市場では、臨床試験が継続的に増加しており、予測期間中に最大の市場シェアを占めると予想されています。臨床試験は、蕁麻疹の根本的なメカニズムや症状の引き金となる要因に関する情報洞察を提供します。この基礎知識は、蕁麻疹の原因に対処する革新的なアプローチの開発に不可欠です。

例えば、2022年6月21日、Celldex Therapeutics, Inc.は、慢性蕁麻疹の治療を目的としたバルゾルボリマブの第2相臨床試験において、最初の患者に投与したと発表しました。バルゾルボリマブはヒト化モノクローナル抗体で、受容体チロシンキナーゼKITに高い特異性で特異的に結合し、その活性を強力に阻害します。

臨床試験は、新薬や治療法を含む新規治療法を試験するためのプラットフォームを提供することで、重要な役割を果たしています。これらの臨床試験の良好な結果は、規制当局の承認や革新的な治療法のイントロダクションつながり、患者が利用できる治療法の選択肢を広げることになります。臨床試験はまた、治療薬の安全性と有効性を検討するのにも役立ちます。

例えば、セルトリオンは2023年4月10日、アレルギー性喘息と慢性蕁麻疹を治療するCT-P39の生物学的同等性を、国際共同第3相臨床試験の24週時点の中間結果を通じて確認しました。CT-P39は、アレルギー性喘息、慢性蕁麻疹、慢性鼻副鼻腔炎を治療する抗体バイオ医薬品であるゾレアのバイオシミラーです。

規制当局の承認取得と新製品の上市も蕁麻疹治療市場の成長を促進

FDA承認などの規制上の承認は、特定の治療法が安全性と有効性のパラメーターを満たしていることを意味します。新製品が規制当局の承認を受けると、市場はより優れた効果的な治療のための幅広い治療選択肢を獲得し、医療従事者は個々の患者のニーズに合わせて安全性と有効性を維持できるようになります。薬事承認は常に、医療上のアンメットニーズをカバーする新規製品の上市に焦点を当てています。

例えば、2023年3月7日。米国食品医薬品局（FDA）は、現在の標準治療であるH1抗ヒスタミン薬による治療では十分にコントロールできない12歳以上の慢性蕁麻疹を有する成人および青年を対象としたデュピクセント（デュピルマブ）の生物製剤追加承認申請を受理しました。FDAの決定目標日は2023年10月22日です。

さらに、規制当局の承認と製品の上市は、効果的な治療法への患者のアクセスを改善することもできます。これらの承認は、革新的な治療が品質基準を満たし、治療の使用に適していることを強化します。そして、より有効で副作用の少ない新規製品の発売は、患者の転帰をより良いものにします。

医薬品に関連する副作用が市場の成長を妨げる

蕁麻疹治療薬には中等度から重度の副作用があるため、予測期間中の市場成長の妨げになると予想されます。患者が特定の薬剤によって顔、手、リンパ節などの腫れなどの副作用を経験した場合、その副作用のために薬剤の採用が減少する可能性があります。その結果、蕁麻疹の管理が不完全になり、症状のコントロールが不十分になります。

さらに、重篤な副作用で有名な症例は、患者や医療提供者の間で安全性への懸念を高めます。そのため、たとえ有効であったとしても、特定の薬や薬剤を使用することに不安が生じ、その結果、それらの治療法に対する全体的な需要が減少することになります。また、副作用のために、患者は代替治療薬を好み、副作用が見られる特定の薬剤の使用を中止します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 臨床試験の増加
    • 規制当局の承認と新製品上市の増加
  • 抑制要因
    • 医薬品に関連する副作用
  • 機会
    • 治療選択肢の進歩
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 慢性蕁麻疹
• 急性蕁麻疹

第8章 治療薬別

• 抗炎症薬
• かゆみ止め
• 抗ヒスタミン薬
• ステロイド外用薬
• 局所麻酔薬
• 免疫抑制剤
• H2拮抗薬
• その他

第9章 投与経路別

• 経口薬
• 局所薬
• 非経口薬

第10章 流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Otsuka Pharmaceutical Co Ltd
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Taiho Pharmaceutical
• Amneal Pharmaceuticals
• Galderma
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals
• Genentech, Inc.
• Sanofi SA

第14章 付録

Market Overview

Global Skin Hives Treatment Market reached US$ 2.6 billion in 2022 and is expected to reach US$ 5.7 billion by 2030 growing with a CAGR of 10.5% during the forecast period 2023-2030.

The global skin hives treatment market experiencing significant growth in recent years mainly owing to the increasing prevalence. The skin hives also known as urticaria, the treatment is based on the type of skin hives that is chronic hives and acute hives. According to the Cleveland Clinic organization, around 20% of the population will get hives at least one time. About 1% to 3% of the population has chronic hives.

There are many types of treatments available, including antihistamines, anti-inflammatory drugs, anti-itch drugs, topical anesthetics, topical steroids, immunosuppressants, and others. The most common and effective treatment is antihistamines. Overall, the global market is expected to experience in the coming years.

Owing to the increasing prevalence of skin hives/urticaria, increasing clinical trials and research activities, rising demand for innovative therapeutics, availability of a wide range of treatment options, increasing awareness and early detection, and advancements in the treatment options, among others are the major factors expected to drive the global skin hives market over the forecast period.

Dynamics

Increasing Clinical Trials Drive the Growth of the Skin Hives Treatment Market

There is a continuously increasing clinical trials in the field of skin hives treatment market, which is expected to hold the largest market share over the forecast period. Clinical trials provide informational insights into the underlying mechanisms of skin hives/urticaria and the factors that trigger the condition. This basic knowledge is essential for the development of innovative approaches that address the causes of urticaria.

For instance, on June 21, 2022, Celldex Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

Clinical trials plays a crucial role by providing a platform for testing novel treatments, including new drugs and therapeutic. Positive results from these trials can lead to regulatory approvals and the introduction of innovative therapies, expanding the range of treatment options available to patients. Clinical trials also helps to address safety and efficacy of the therapeutics.

For instance, on April 10, 2023, Celltrion confirmed the bioequivalence of CT-P39 to treat allergic asthma and chronic urticaria, through its interim results from its global phase 3 clinical trials at 24 weeks. CT-P39 is a biosimilar referencing Xolair, which is an antibody biopharmaceutical that treats allergic asthma, chronic urticaria, and chronic rhinosinusitis.

Rising Regulatory Approvals and Novel Product Launches Also Drive the Growth of the Skin Hives Treatment Market

Regulatory approvals such as FDA approvals signify that the particular treatment has met a safety and efficacy parameters. As a new products receive regulatory approvals, the market gains a wider range of treatment options for better and more effective treatment, allowing healthcare providers to maintain the safety and efficacy of individual patient needs. The regulatory approvals always focus on novel product launches to cover the unmet medical needs.

For instance, on March 7, 2023. The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment. The target action date for the FDA decision is October 22, 2023.

Moreover, the regulatory approvals and product launches can also improves the patient's access to effective treatments. These approvals enhance the innovative treatments meet quality standards and are suitable for the usage of the treatment. And the novel product launches with more effectiveness and lesser side effects results in the better patient outcomes.

Adverse Effects Associated with Drugs Will Hamper the Growth of the Market

There are moderate to severe adverse effects associated with the skin hives drugs, this may be expected to hamper the market growth over the forecast period. If the patients experience adverse effects such as swelling in the face, hands, lymph nodes, and others from a particular drug, there may be a reduced adoption of the drugs due to their side effects. This results in incomplete management of urticaria, leading to inadequate symptom control.

Furthermore, high-profile cases of the severe side effects raise the safety concerns among patients and healthcare providers. This can lead to uncertainty in using certain drugs and medications, even if they are effective, thereby reducing the overall demand for those treatments. Due to the adverse effects, patients also prefer the alternative therapeutics and discontinue the usage of the particular drugs which shows the adverse effects.

Segment Analysis

The global skin hives treatment market is segmented based on type, treatment, route of administration, distribution channel, and region.

The Antihistamines from the Treatment Segment Accounted for Approximately 37.8% of the Skin Hives Treatment Market Share

Antihistamines are the most commonly used therapeutics for the treatment of skin hives or urticaria and holds the largest market share over the forecast period. They are very effective in providing relief from itching for patients with urticaria and reducing the symptoms of skin hives for many individuals. They are often considered a first-line treatment for patients who are suffering from acute urticaria. Many ongoing clinical trials, research activities, and regulatory approvals provide better and enhanced antihistamines.

For instance, on August 9, 2023, Novartis announced that the two Phase III trials for the antihistamine drug, remibrutinib have demonstrated clinical efficacy and met their primary endpoints in patients with chronic spontaneous urticaria. Remibrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor. It acts by stopping histamine release by blocking the BTK cascade. The release of histamine is responsible for chronic spontaneous urticaria symptoms such as itching, hives, and swelling.

Moreover, many antihistamines are also available over-the-counter without the need for a prescription, a benefit for the patients. This accessibility makes them a convenient option for individuals experiencing mild to moderate hives. The antihistamines are also available in various formulations such as topical agents, oral tablets, and liquids.

Geographical Penetration

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure

North America accounted for the largest market share over the forecast period owing to the presence of major players in the region and advanced healthcare infrastructure with advanced research activities. The region is home to several major pharmaceutical companies, these companies invest in the development of new drugs and therapeutics for better treatment of skin hives.

For instance, on October 18, 2022, Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration has approved Allegra(R) (fexofenadine hydrochloride) oral suspension for the twice-daily treatment of symptoms associated with seasonal allergies in pediatric patients, 2 to 11 years of age, and for the treatment of chronic idiopathic urticaria in children 6 months to 11 years of age. This approval makes available a safe and effective seasonal allergy and urticaria treatment option.

Furthermore, North America is a well-known region for its well-established and advanced healthcare infrastructure including hospitals, dermatology clinics for effective treatment, and a wide range of pharmacies for urticaria drugs. This advanced healthcare infrastructure supports early detection, diagnosis, and treatment and also helps in research activities and clinical trials for therapeutic novel innovations.

Competitive Landscape

The major global players in the skin hives treatment market include Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical, Amneal Pharmaceuticals, Galderma, F. Hoffmann-La Roche Ltd, Novartis AG, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Genentech, Inc., and Sanofi SA among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global skin hives treatment market. Many clinical trials, FDA approvals, and research activities related to the urticaria treatment are temporarily disrupted and discontinued due to the redirected focus towards COVID-related studies, impacted the market globally. Moreover, during the pandemic, non-urgent treatments are postponed due to the lockdown instructions, which leads to delayed diagnosis and treatment of skin hives.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global skin hives treatment market. During the conflict, the import and export of raw materials and approved drugs are temporarily disrupted due to conflict issues. Many research activities and clinical trials are disrupted temporarily and due to the less presence of major players in the region, there is a moderate impact on the global market.

By Type

• Chronic Hives
• Acute Hives

By Treatment

• Anti-Inflammatory Drugs
• Anti-Itch Drugs
• Antihistamines
• Topical Steroids
• Topical Anesthetics
• Immunosuppressants
• H2 Antagonists
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On February 2, 2023, Amgen and AstraZeneca announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma and chronic urticaria. TEZSPIRE is also in development for other potential indications including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and eosinophilic esophagitis (EoE).
• On January 05, 2023, Novelty Nobility, a Korean company specializing in antibody new drug development, announced that its U.S. partner, ValenzaBio, was acquired by Acelyrin. It also announced that Novelty Nobility transferred NN2802, a pre-IND anti-c-KIT being studied as a treatment option in chronic urticaria, to ValenzaBio for a total of $733.25 million.
• On March 01, 2022, Nuvo Pharmaceuticals Inc. and Miravo Healthcare a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. has launched Blexten for pediatric use in patients 4 years of age and older. Blexten is a second-generation antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.

Why Purchase the Report?

• To visualize the global skin hives treatment market segmentation based on type, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of skin hives treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global skin hives treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

DataM Intelligence Opinion:

According to the DataM Intelligence, the skin hives treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global skin hives treatment market in the upcoming years.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Clinical Trials
    • 4.1.1.2. Increasing Regulatory Approvals and Novel Product Launches
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects Associated with Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancements in Treatment Options
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Chronic Hives *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Acute Hives

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment
• 8.2. Anti-Inflammatory Drugs *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Anti-Itch Drugs
• 8.4. Antihistamines
• 8.5. Topical Steroids
• 8.6. Topical Anesthetics
• 8.7. Immunosuppressants
• 8.8. H2 Antagonists
• 8.9. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Topical
• 9.4. Parenteral

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Otsuka Pharmaceutical Co Ltd *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Taiho Pharmaceutical
• 13.3. Amneal Pharmaceuticals
• 13.4. Galderma
• 13.5. F. Hoffmann-La Roche Ltd
• 13.6. Novartis AG
• 13.7. Dr. Reddy's Laboratories
• 13.8. Glenmark Pharmaceuticals
• 13.9. Genentech, Inc.
• 13.10. Sanofi SA

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us